Bacterial flagellar capping proteins adopt diverse oligomeric states

  1. Sandra Postel
  2. Daniel Deredge
  3. Daniel A Bonsor
  4. Xiong Yu
  5. Kay Diederichs
  6. Saskia Helmsing
  7. Aviv Vromen
  8. Assaf Friedler
  9. Michael Hust
  10. Edward H Egelman
  11. Dorothy Beckett
  12. Patrick L Wintrode
  13. Eric J Sundberg  Is a corresponding author
  1. University of Maryland School of Medicine, United States
  2. University of Maryland School of Pharmacy, United States
  3. University of Virginia, United States
  4. University of Konstanz, Germany
  5. Technische Universitaet Braunschweig, Germany
  6. The Hebrew University of Jerusalem, Israel
  7. Technische Universität Braunschweig, Germany
  8. University of Maryland College Park, United States

Abstract

Flagella are critical for bacterial motility and pathogenesis. The flagellar capping protein (FliD) regulates filament assembly by chaperoning and sorting flagellin (FliC) proteins after they traverse the hollow filament and exit the growing flagellum tip. In the absence of FliD, flagella are not formed resulting in impaired motility and infectivity. Here, we report the 2.2 Å resolution X-ray crystal structure of FliD from Pseudomonas aeruginosa, the first high-resolution structure of any FliD protein from any bacterium. In combination with a multitude of biophysical and functional analyses, we find that Pseudomonas FliD exhibits unexpected structural similarity to other flagellar proteins at the domain level, adopts a unique hexameric oligomeric state, and depends on flexible determinants for oligomerization. Considering that the flagellin filaments on which FliD oligomers are affixed vary between bacteria in protofilament number, our results suggest that FliD oligomer stoichiometries vary across bacteria to complement their filament assemblies.

Article and author information

Author details

  1. Sandra Postel

    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6717-1870
  2. Daniel Deredge

    Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, United States
    Competing interests
    No competing interests declared.
  3. Daniel A Bonsor

    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  4. Xiong Yu

    Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, United States
    Competing interests
    No competing interests declared.
  5. Kay Diederichs

    Department of Biology, University of Konstanz, Konstanz, Germany
    Competing interests
    No competing interests declared.
  6. Saskia Helmsing

    Department of Biotechnology, Institute of Biochemistry, Biotechnology and Bioinformatics, Technische Universitaet Braunschweig, Braunschweig, Germany
    Competing interests
    No competing interests declared.
  7. Aviv Vromen

    Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel
    Competing interests
    No competing interests declared.
  8. Assaf Friedler

    Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel
    Competing interests
    No competing interests declared.
  9. Michael Hust

    Department of Biotechnology, Institute of Biochemistry, Biotechnology and Bioinformatics, Technische Universität Braunschweig, Braunschweig, Germany
    Competing interests
    No competing interests declared.
  10. Edward H Egelman

    Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, United States
    Competing interests
    Edward H Egelman, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4844-5212
  11. Dorothy Beckett

    Department of Chemistry and Biochemistry, University of Maryland College Park, Baltimore, United States
    Competing interests
    No competing interests declared.
  12. Patrick L Wintrode

    Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, United States
    Competing interests
    No competing interests declared.
  13. Eric J Sundberg

    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States
    For correspondence
    ESundberg@ihv.umaryland.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0478-3033

Funding

National Center for Research Resources (NIH S10 RR15899)

  • Dorothy Beckett

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Richard M Berry, University of Oxford, United Kingdom

Version history

  1. Received: June 15, 2016
  2. Accepted: September 23, 2016
  3. Accepted Manuscript published: September 24, 2016 (version 1)
  4. Version of Record published: October 20, 2016 (version 2)

Copyright

© 2016, Postel et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,387
    views
  • 534
    downloads
  • 38
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sandra Postel
  2. Daniel Deredge
  3. Daniel A Bonsor
  4. Xiong Yu
  5. Kay Diederichs
  6. Saskia Helmsing
  7. Aviv Vromen
  8. Assaf Friedler
  9. Michael Hust
  10. Edward H Egelman
  11. Dorothy Beckett
  12. Patrick L Wintrode
  13. Eric J Sundberg
(2016)
Bacterial flagellar capping proteins adopt diverse oligomeric states
eLife 5:e18857.
https://doi.org/10.7554/eLife.18857

Share this article

https://doi.org/10.7554/eLife.18857

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Damien M Rasmussen, Manny M Semonis ... Nicholas M Levinson
    Research Article

    The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation, we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.

    1. Structural Biology and Molecular Biophysics
    Nicholas James Ose, Paul Campitelli ... Sefika Banu Ozkan
    Research Article

    We integrate evolutionary predictions based on the neutral theory of molecular evolution with protein dynamics to generate mechanistic insight into the molecular adaptations of the SARS-COV-2 spike (S) protein. With this approach, we first identified candidate adaptive polymorphisms (CAPs) of the SARS-CoV-2 S protein and assessed the impact of these CAPs through dynamics analysis. Not only have we found that CAPs frequently overlap with well-known functional sites, but also, using several different dynamics-based metrics, we reveal the critical allosteric interplay between SARS-CoV-2 CAPs and the S protein binding sites with the human ACE2 (hACE2) protein. CAPs interact far differently with the hACE2 binding site residues in the open conformation of the S protein compared to the closed form. In particular, the CAP sites control the dynamics of binding residues in the open state, suggesting an allosteric control of hACE2 binding. We also explored the characteristic mutations of different SARS-CoV-2 strains to find dynamic hallmarks and potential effects of future mutations. Our analyses reveal that Delta strain-specific variants have non-additive (i.e., epistatic) interactions with CAP sites, whereas the less pathogenic Omicron strains have mostly additive mutations. Finally, our dynamics-based analysis suggests that the novel mutations observed in the Omicron strain epistatically interact with the CAP sites to help escape antibody binding.